Company profile
UK company SC612928, incorporated on 6 November 2018.
Macomics | Macrophage biology. Revealed
We develop precision medicines to modulate macrophages for the treatment of cancer, by bringing together world-leading cancer biologists.
Company number SC612928
Updated 07 Jul 2026 09:49
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzU1NTQwMTcwMmFkaXF6a2N4
Published 11 Nov 2026 12:13
PSC07 | Transaction MzU1NTQwMTIzNmFkaXF6a2N4
Published 11 Nov 2026 12:10
SH01 | Transaction MzU1NDYxMDA0MWFkaXF6a2N4
Published 05 Nov 2026 15:43
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Macomics develops cancer therapeutics using antibody-based treatments.
As a result of our work we founded a Startup called Macomics on November 6th 2018; we are now in the process of defining a business plan and we are in a phase of advanced negotiations with an investor.
No impact. Looking for external investment.
